CION Ameerpet
Lung Cancer Immunotherapy · Pneumonitis Risk
Pneumonitis Risk in Lung Cancer Patients — Who Is at Risk on Immunotherapy, and Why
Immunotherapy is not an option for most lung cancer patients in India — eligibility turns on biomarker testing, driver mutations and stage, not on the diagnosis alone. For the patients who do start it, immune-related pneumonitis is the reaction that matters most: inflammation of lung tissue caused by the immune system itself. ASCO and NCCN guidance on immune-related adverse events treats any new or worsening breathing symptom on immunotherapy as needing same-day assessment.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Most patients are not candidates — eligibility for immunotherapy is decided by biomarker and driver-mutation testing, not by a lung cancer diagnosis on its own.
- Existing lung disease raises the risk — fibrosis, significant COPD and earlier radiotherapy to the chest all increase the chance of immune pneumonitis.
- It is the change that matters — you may already cough and already be breathless, so the signal is any shift from your own baseline.
- Never wait a breathing symptom out — a new or worsening cough needs same-day review; breathlessness at rest is an emergency room visit.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Eligibility first
Is Immunotherapy an Option for Most Lung Cancer Patients in India?
No. Most lung cancer patients in India are not candidates for immunotherapy. Eligibility is decided by biomarker testing and the stage of disease, not by the diagnosis alone. Patients with an EGFR, ALK or ROS1 driver mutation are usually treated with targeted therapy first, and checkpoint inhibitors are not the preferred option for them.
Even where immunotherapy is clinically appropriate, cost and access rule it out for many families in Telangana and Andhra Pradesh. We say this at the top of the page on purpose. A page about the risk of a treatment is dishonest if it lets you assume the treatment was yours to have in the first place. If eligibility is the question you actually came with, start with PD-L1 testing in lung cancer and the cost of immunotherapy for lung cancer in India.
- PD-L1 expression on your tissue — reported as a score, not a yes or no, and it influences whether immunotherapy is used alone or alongside chemotherapy.
- Driver mutation testing — an EGFR, ALK or ROS1 result usually moves you to targeted therapy first.
- Stage and treatment intent — what the treatment is meant to achieve changes what risk is reasonable to accept.
- Performance status — how well you are functioning day to day, recorded as an ECOG score.
- Your baseline lungs — interstitial lung disease, fibrosis, severe COPD or earlier radiotherapy to the chest all weigh on the decision.
- Autoimmune disease, transplant or ongoing high-dose steroids — each of these needs a specific discussion before immunotherapy is considered at all.
Already on immunotherapy and short of breath? Go to the nearest emergency room now, or call an ambulance, if you have any of these:
- Breathlessness at rest, or breathlessness that stops you finishing a sentence
- Bluish lips or fingertips
- Chest pain or a racing heartbeat
- Confusion, severe drowsiness or fainting
For a new cough or breathlessness that is not one of the above, call the CION helpline the same day. There is no safe wait-and-watch step for a new breathing symptom on immunotherapy.
Call the CION Helpline Now: 1800 202 8726
Risk factors
Is Pneumonitis Risk Higher If You Already Have Lung Disease?
Yes. Pre-existing interstitial lung disease, pulmonary fibrosis, significant COPD and previous radiotherapy to the chest all raise the risk of immune-related pneumonitis. Lung cancer patients also sit higher than several other cancer groups, because the lung is already the diseased organ. None of these automatically rules immunotherapy out. They change how closely you are watched.
Published ASCO and NCCN guidance on managing immune-related adverse events puts pneumonitis of any severity at roughly 3–5% of patients treated with a single PD-1 or PD-L1 inhibitor, with higher figures reported when two checkpoint inhibitors are combined and in patients treated after radiotherapy to the chest. These are indicative ranges from guideline literature as of August 2026. They describe a population, not a prediction for any one person.
| Risk factor | Why it raises pneumonitis risk | What usually changes in your plan |
|---|---|---|
| Interstitial lung disease or pulmonary fibrosis | Lung tissue is already scarred, so there is little reserve if inflammation is added on top. | A careful tumour board discussion before starting. Some patients are advised against immunotherapy. |
| Significant COPD or long-standing smoking damage | Airflow is already limited, so a small drop in lung function is felt much sooner. | Baseline lung function and oxygen saturation recorded, with a closer symptom review each cycle. |
| Previous radiotherapy to the chest | Radiotherapy leaves its own inflammatory changes in lung tissue, which overlap with pneumonitis on a scan. | Radiation records and older scans reviewed alongside every new image. |
| Two immunotherapy drugs together | Combination checkpoint blockade is reported to cause immune reactions more often than a single drug. | A tighter monitoring schedule and a lower threshold for arranging a CT chest. |
| The lung as the site of disease | The tumour itself causes cough and breathlessness, which masks the earliest signs of pneumonitis. | A written record of your usual symptoms, so any change can be measured rather than guessed. |
| Low baseline oxygen saturation | There is less margin between a mild symptom and an emergency. | An agreed oxygen number below which you are told to attend the emergency room. |
Did you know?
Immune-related pneumonitis is reported more often in lung cancer than in several other cancers treated with checkpoint inhibitors, and more often again when two immunotherapy drugs are combined or when immunotherapy follows radiotherapy to the chest. (Source: ASCO and NCCN guidance on managing immune-related adverse events.)
Early recognition
What Are the Early Signs of Pneumonitis in a Lung Cancer Patient?
The early signs are a new or worsening dry cough, breathlessness doing something you managed easily last week, chest tightness, and sometimes a low-grade fever. In lung cancer these symptoms already exist at some level. What matters is the change from your own baseline, not the symptom itself.
This is the trap specific to lung cancer. A patient with melanoma who develops a cough notices it immediately. A lung cancer patient has been coughing for months and reasonably assumes it is the tumour, the monsoon, or the same COPD they have lived with for years. That assumption is why pneumonitis is caught later in this group than in any other.
| Stage | What is typically happening |
|---|---|
| Typically starts | Most often between about 6 and 24 weeks after the first infusion — but it can begin after a single dose, or, less commonly, months after treatment has ended. |
| Earliest phase | A dry cough, or breathlessness only on effort. Easy to put down to the cancer, to COPD, or to a change in weather. |
| Days later, if unreported | Breathlessness with less and less effort, falling oxygen levels, sometimes a low-grade fever. |
| Emergency stage | Breathlessness at rest, bluish lips or fingertips, confusion. This is an emergency room visit, not a clinic appointment. |
There is no home-management step for a new or worsening breathing symptom on immunotherapy. Do not start a cough syrup, an inhaler that was not prescribed for this, or a leftover course of antibiotics and wait to see what happens. The correct response is always to be assessed the same day, or to go to the emergency room for the red-flag symptoms above.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a Clear Answer on Immunotherapy and Your Lungs
Every plan goes through a tumour board — medical, radiation and pulmonary input together, not one doctor's opinion.
What monitoring looks like
What Monitoring Should a Lung Cancer Patient on Immunotherapy Expect?
Monitoring starts before the first infusion, not after a symptom appears. Expect a baseline chest scan, a record of your usual breathing and oxygen level, and a structured symptom review before every cycle. Any new or worsening breathing symptom triggers same-day assessment, a CT chest, and tests to rule out infection.
- 1
Baseline recorded before you start
Oxygen saturation, lung function where relevant, a baseline CT chest, and a written note of the cough and breathlessness you already live with. Any interstitial lung disease, fibrosis or earlier chest radiotherapy is documented here.
- 2
A symptom review at every cycle
Immunotherapy is given as day care at CION centres. Before the infusion runs, you are asked directly about breathing, cough, chest tightness and effort tolerance — not left to raise it yourself.
- 3
Your own baseline diary between cycles
Note how far you can walk before stopping, how many pillows you sleep on, and your pulse oximeter reading if you have one. This is for reporting, not for self-treatment: a number you can quote makes a same-day decision faster and better.
- 4
An agreed threshold to call
Your team should tell you the specific change that means call today, and the specific change that means go to the emergency room. If nobody has given you those two lines, ask for them at your next cycle.
- 5
Imaging, and ruling out infection
A CT chest is compared against your earlier scans, while swabs or sputum are checked for infection. Response-assessment PET-CT is coordinated at partner imaging centres rather than performed in-house, and old radiotherapy fields are reviewed alongside.
- 6
A tumour board decision, not one doctor's
If pneumonitis is confirmed, immunotherapy is usually paused and steroids are started under specialist supervision. Whether treatment restarts later is decided by the board with you, based on severity and how completely your lungs recover.
Why this group
Why Lung Cancer Patients Are the Highest-Risk Group for Pneumonitis
Lung cancer is the largest immunotherapy population in India, and it carries a higher reported pneumonitis risk than most other common indications. Four things stack up: the lung is the diseased organ, many patients have smoking-related damage, chest radiotherapy is common in the pathway, and the cancer itself produces the very symptoms pneumonitis first causes.
- The target organ is already sick — inflammation lands on tissue that is already carrying a tumour, and often scarring as well.
- Smoking history is common — years of airflow limitation mean a smaller drop in lung function produces a bigger symptom.
- Chest radiotherapy is part of many plans — radiation changes and immune pneumonitis can look similar on imaging, which slows the diagnosis unless old scans are on hand.
- Combination regimens are frequent — immune reactions are reported more often when two checkpoint inhibitors are used together.
- The warning signs are camouflaged — cough and breathlessness are already the daily experience of lung cancer, so the earliest signal is easy to dismiss.
None of this is an argument against immunotherapy where it is genuinely indicated. It is an argument for a documented baseline, a named threshold to call, and a team that treats a changed cough as a clinical event rather than a nuisance. Pneumonitis caught early is usually manageable. Pneumonitis reported late is the immune reaction most likely to become life-threatening quickly.
Care during treatment
Lung Reactions Are Manageable When They Are Caught Early
Patients who report a change in their breathing promptly are supported by the same multidisciplinary team through every cycle.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Pneumonitis Risk on Lung Cancer Immunotherapy: Your Questions Answered
Is the risk of pneumonitis higher if I already have lung disease?
Yes. Pre-existing interstitial lung disease, pulmonary fibrosis, significant COPD and previous radiotherapy to the chest are all recognised in ASCO and NCCN guidance as factors that raise the risk of immune-related pneumonitis. Lung cancer patients as a group are also affected more often than patients with several other cancers, because the lung is already the diseased organ. Having one of these conditions does not automatically rule immunotherapy out. It changes the conversation: your team weighs the risk against the expected benefit, records a careful baseline, and reviews your breathing more closely at every cycle.
What are the early signs of pneumonitis in a lung cancer patient?
A new or worsening dry cough, breathlessness while doing something you managed easily a week or two ago, chest tightness, and sometimes a low-grade fever. In lung cancer this is harder than it sounds, because a cough and some breathlessness may already be part of daily life. The signal is the change from your own baseline, not the presence of the symptom. If you could climb one flight of stairs last week and cannot today, that is a change worth reporting the same day, even if it feels small.
What monitoring should I expect while on immunotherapy for lung cancer?
Monitoring begins before the first infusion. Your team records a baseline: a chest scan, oxygen saturation, lung function where relevant, and a note of the cough or breathlessness you already live with. Before every cycle in day care you are asked directly about breathing, cough and chest symptoms. Blood tests check thyroid, liver and kidney function alongside. Scans are repeated at planned intervals, and response-assessment PET-CT is coordinated at partner imaging centres. Any new or worsening breathing symptom between cycles is reviewed the same day, not at the next appointment.
Can I still have immunotherapy if I have COPD or pulmonary fibrosis?
Sometimes, and sometimes not. Significant interstitial lung disease or pulmonary fibrosis is a serious concern, because inflammation on top of already scarred lungs leaves very little reserve. Stable, well-controlled COPD is a different situation and is often manageable with closer monitoring. This is a tumour board decision rather than one doctor's call, and it depends on your lung function, your oxygen levels, what other treatment options exist, and what you want. Choosing a different treatment, or not treating, is a legitimate option that should be discussed openly.
How is pneumonitis told apart from a chest infection or the cancer getting worse?
The three can look identical from symptoms alone, which is why the answer comes from tests rather than guesswork. Your team arranges a CT scan of the chest and compares its pattern against your earlier scans. Samples are sent to check for bacterial or viral infection, because an infection needs antibiotics while pneumonitis needs a different treatment entirely. Cancer progression is assessed on the same imaging, usually with a pulmonologist and radiologist involved. Treating a suspected chest infection with antibiotics alone, without asking whether it could be immune-related, is the mistake this page exists to prevent.
Does having pneumonitis mean immunotherapy stops for good?
Not always. Immunotherapy is usually paused rather than permanently stopped while pneumonitis is treated with steroids under specialist supervision and monitored with repeat scans and oxygen checks. Whether it can restart depends on how severe the reaction was, how completely your lungs recovered, and what other options you have. Milder reactions are more often followed by a restart. A severe reaction, or one that returns, usually means immunotherapy is stopped and the plan is changed. Your tumour board makes that call with you, not for you.